HIT Consultant June 5, 2024
What You Should Know:
– Nucleus RadioPharma, the world’s first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
– The strategic investment bolsters Nucleus’ mission to make targeted radiotherapies and theranostics more accessible to patients worldwide.
AstraZeneca Joins Forces with Leading Radiopharmaceutical Innovator
AstraZeneca joins a distinguished group of existing investors, including GE Healthcare, Mayo Clinic, and Eclipse Ventures. This combined financial backing empowers Nucleus to accelerate the development, supply, and commercial manufacturing of radiopharmaceuticals, a promising advancement in oncology.
Dr. Tyrell Rivers Appointed to Board of Directors
Concurrent with the funding announcement, Nucleus named Dr. Tyrell Rivers to its Board of Directors. Dr....
Today's Sponsors
Today's Sponsor